Document text
Principal Investigator: Erica Ollmann Saphire
Organization: LA JOLLA INSTITUTE FOR IMMUNOLOGY
Fiscal Year: 2020
Award: $2,688,763
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effort
to conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spike
protein contributed by a range of large and small companies and academic labs on multiple continents. CoVIC
provides an opportunity for side-by-side analysis of the leading therapeutic candidates under the same assay
conditions, as well as real-time collaborative assembly of a broader, deeper dataset on the activities and
potencies of antibodies against SARS-CoV-2 than could be assembled by any single discovery effort alone. The
currently funded CoVIC studies focus largely on characteristics of the Fab region of the IgG therapeutic: binding
and mechanical neutralization, and analyze only spike from the original Wuhan reference strain of SARS-CoV-
2. The proposed supplement will provide support for critical components that are currently missing from CoVIC
but which are needed to accelerate clinical advancement of antibodies that will be safe, efficacious and offer
durable protection. We will determine Fc-mediated activities of the therapeutic antibodies, the likelihood or risk
of enhancement from clinical candidates, and which epitopes and sites of and susceptibility to mutagenic escape.
The resulting body of information will inform early and next-generation antibody therapies and will ensure that
therapeutics are known which are responsive to emerging viral variants.
Terms: <2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Ab-mediated immunity><Ab-mediated protection><Address><Affinity><Antibodies><Antibody Therapy><Antibody-mediated protection><Antigen-Antibody Complex><Antigenic Determinants><Area><Assay><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Blinded><Characteristics><Clinical><Clinical Research><Clinical Study><Complement><Complement Proteins><Complex><Coronaviridae><Coronavirus><Cryo-electron Microscopy><Cryoelectron Microscopy><Data><Data Bases><Data Set><Databases><Dataset><Electron Cryomicroscopy><Engineering><Ensure><Epitopes><FAIR data><FAIR principles><FcRn><FcRn neonatal transfer protein><Findable, Accessible, Interoperable, and Reusable><Funding><Geometry><Half-Life><Human><IgG><Immune Complex><Immunoglobulin G><Immunotherapeutic agent><In Vitro><International><Knowledge><Maps><Mechanics><Mediating><Membrane><Modern Man><Molecular Interaction><Myeloid Cells><NIH><National Institutes of Health><Participant><Population><Predisposition><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><Race><Racial Group><Racial Stocks><Research Grants><Research Project Grants><Research Projects><Risk><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Serologic tests><Serological Tests><Severe acute respiratory syndrome coronavirus 2><Side><Site><Speed><Structure><Surface><Survey Instrument><Surveys><Susceptibility><System><Therapeutic><Therapeutic antibodies><Time><Transgenic Model><United States National Institutes of Health><Variant><Variation><Viral><Wuhan coronavirus><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antibody-mediated immunity><clinical candidate><corona virus><cryo-EM><cryoEM><data base><experiment><experimental research><experimental study><immune drugs><immune-based therapeutics><immunologic preparation><immunologic therapeutics><immunotherapeutics><immunotherapy agent><mechanical><membrane structure><mouse model><murine model><neonatal Fc receptor><next generation><novel><programs><serology><therapeutic candidate><tool><transgenic trait>